Bigfoot’s diabetes management system is designed to address problems such as missed doses, inadequate insulin intensification and dosing errors that affect people with diabetes who require multiple daily injections. The system integrates with Abbott’s FreeStyle Libre CGM to incorporate glucose data and provide real-time glycemic alerts.
To see how its system performs in the real world, Bigfoot analyzed clinical outcomes data on 58, mostly type 2 diabetes, people. The researchers found improvements in glycaemic control, reporting that the 36 users with prior CGM experience had a baseline HbA1c of 8.2% and GMI at six months of 7.3%. In the 12 users without prior CGM experience, the baseline HbA1c and six-month GMI figures were 9.0% and 7.1%, respectively. Glucose levels were low 1.4% of the time and very low 0.2% of the time.
“These data indicate that, for this cohort consisting primarily of older adults with type 2 diabetes who were on [multiple daily injection] therapy with suboptimal glycemic control, using the system has the potential for rapid and durable improvement in glycemic control,” the researchers concluded.
To find out more, CLICK HERE.
